References

Amarapurka, D.N., A.D. Amarapurkar, N.D. Patel, S. Agal, R. Baigal, P. Gupte and S. Pramanik, 2006. Nonalcoholic steatohepatitis (NASH) with diabetes: Predictors of liver fibrosis. Ann. Hepatol., 5: 30-33.
PubMed  |  

Angulo, P., 2007. GI epidemiology: Nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther., 25: 883-889.
PubMed  |  

Bai, L., Y. Jia, N. Viswakarma, J. Huang and A. Vluggens, 2011. Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse. Hepatology, 53: 1164-1174.
PubMed  |  

Chan, D.F., A.M. Li, W.C. Chu, M.H. Chan and E.M. Wong et al., 2004. Hepatic steatosis in obese Chinese children. Obes. Rev., 5: 27-42.
PubMed  |  

Chitturi, S., S. Abeygunasekera, G.C. Farrell, J. Holmes-Walker and J.M. Hui et al., 2002. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology, 35: 373-379.
CrossRef  |  PubMed  |  Direct Link  |  

Clark, J.M. and A.M. Diehl, 2003. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA, 289: 3000-3004.

Diehl, A.M., Z. Goodman and K.G. Ishak, 1988. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology, 95: 1056-1062.
PubMed  |  

Drucker, D.J. and A.B. Goldfine, 2011. Cardiovascular safety and diabetes drug development. Lancet, 377: 977-979.
CrossRef  |  

Fan, J. and T. Watanabe, 2003. Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmocol. Ther., 99: 261-282.
CrossRef  |  PubMed  |  Direct Link  |  

Fan, J.G. and G.C. Farrell, 2009. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol., 50: 204-210.
Direct Link  |  

Folch, J., M. Lees and G.H.S. Stanley, 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem., 226: 497-509.
CrossRef  |  PubMed  |  Direct Link  |  

Garcia-Ruiz, I., C. Rodriguez-Juan, T. Diaz-Sanjuan, M.A. Martinez, T. Munoz-Yague and J.A. Solis-Herruzo, 2007. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. Hepatology, 46: 414-423.
PubMed  |  

Home, P.D., S.J. Pocock, H. Beck-Nielsen, P.S. Curtis and R. Gomis et al., 2009. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet, 373: 2125-2135.
CrossRef  |  Direct Link  |  

Home, P.D., S.J. Pocock, H. Beck-Nielsen, R. Gomis and M. Hanefeld et al., 2007. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N. Engl. J. Med., 357: 28-38.
Direct Link  |  

Kawai, T., T. Ito, K. Ohwada, Y. Mera, M. Matsushita and H. Tomoike, 2006. Hereditary postprandial hypertriglyceridemic rabbit exhibits insulin resistance and central obesity. A novel model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 26: 2752-2757.

Lago, R.M., P.P. Singh and R.W. Nesto, 2007. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet, 370: 1129-1136.

Liu, E., S. Kitajima, Y. Higaki, M. Morimoto and H. Sun et al., 2005. High lipoprotein lipase activity increases insulin sensitivity in transgenic rabbits. Metabolism, 54: 132-138.
PubMed  |  

Marchesini, G., E. Bugianesi and G. Forlani, 2003. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology, 37: 917-923.

Neuschwander-Tetri, B.A., 2009. Lifestyle modification as the primary treatment of NASH. Clin. Liver Dis., 13: 649-665.

Neuschwander-Tetri, B.A., E.M. Brunt, K.R. Wehmeier, D. Oliver and B.R. Bacon, 2003. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 38: 1008-1017.
PubMed  |  Direct Link  |  

Otogawa, K., K. Kinoshita, H. Fujii, M. Sakabe and R. Shiga et al., 2007. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation and fibrosis in a rabbit model of steatohepatitis: Implications for the pathogenesis of human nonalcoholic steatohepatitis. Am. J. Pathol., 170: 967-980.

Ratziu, V., F. Charlotte, C. Bernhardt, P. Giral, M. Halbron and G. Lenaour, 2010. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology, 51: 445-453.
PubMed  |  

Rosen, C.J., 2010. Revisiting the rosiglitazone story-lessons learned. N. Engl. J. Med., 363: 803-806.
Direct Link  |  

Tahan, V., F. Eren, E. Avsar, D. Yavuz and M. Yuksel et al., 2007. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Digestive Dis. Sci., 52: 3465-3472.
CrossRef  |  PubMed  |  

Wang, C.H., C.H. Leung, S.C. Liu and C.H. Chung, 2006. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. J. Formos. Med. Assoc., 105: 743-752.
Direct Link  |  

Wang, H.N., Y.R. Wang, G.Q. Liu, Z. Liu, P.X. Wu, X.L. Wei and T.P. Hong, 2008. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J. Gastroenterol., 14: 7240-7246.

Williams, R., 2006. Global challenges in liver disease. Hepatology, 44: 521-526.
PubMed  |  

Yki-Jarvinen, H., 2010. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: Human data. Curr. Opin. Clin. Nutr. Metab. Care, 13: 709-714.
PubMed  |  

Zhao, S., C. Zhang, Y. Lin, P. Yang and Q. Yu, et al., 2008. The effects of rosiglitazone on aortic atherosclerosis of cholesterol-fed rabbits. Thromb. Res., 123: 281-287.
PubMed  |  

Zhao, S., Y. Chu, C. Zhang, Y. Lin and K. Xu et al., 2008. Diet-induced central obesity and insulin resistance in rabbits. J. Anim. Physiol. Anim. Nutr., 92: 105-111.
CrossRef  |  PubMed  |